| Symbol | KLRS |
|---|---|
| Name | KALARIS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1100 WINTER STREET,SUITE 500, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 212 915 2577 |
| Fax | — |
| — | |
| Website | https://www.kalaristx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001754068 |
| Description | Kalaris was founded by experienced leaders in ophthalmology drug development and commercialization to address a major unmet need in the treatment of retinal diseases.Existing therapies for retinal neovascular / exudative diseases have made great strides in preserving or improving vision, but they require frequent clinic visits over many years that place a significant burden on patients and caregivers. This onerous visit regimen often leads to missed or delayed injections and suboptimal patient outcomes. Additional info from NASDAQ: |
(30% Negative) KALARIS THERAPEUTICS, INC. (KLRS) Reports Q3 2026 Financial Results
Read moreKalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Read moreKEATING LAURIE 🟢 acquired 18.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $3.51 Transaction Date: Aug 01, 2026 | Filing ID: 330530
Read moreNew Form 3 - Kalaris Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001193125-26-330516 <b>Size:</b> 26 KB
Read moreBayko Liisa Ann 🟢 acquired 220.0K shares (1 derivative) of Kalaris Therapeutics, Inc. (KLRS) at $4.00 Transaction Date: Jul 20, 2026 | Filing ID: 309047
Read moreNew Form 3 - Kalaris Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001193125-26-309027 <b>Size:</b> 28 KB
Read more(99% Neutral) KALARIS THERAPEUTICS, INC. (KLRS) Announces New Board Appointment
Read more(30% Negative) KALARIS THERAPEUTICS, INC. (KLRS) Announces Delay in treatments Trials for prevalent retinal diseases Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreKalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Read more(99% Neutral) KALARIS THERAPEUTICS, INC. (KLRS) Announces New Board Appointment
Read more